Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BGM NASDAQ:CCCC NASDAQ:NRIX NASDAQ:SANA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBGMBGM Group$7.41-2.9%$8.86$6.05▼$17.17$741.80M1.2625,631 shs6,886 shsCCCCC4 Therapeutics$2.67+4.3%$2.22$1.09▼$7.22$182.20M2.981.60 million shs1.31 million shsNRIXNurix Therapeutics$9.12-3.6%$10.99$8.18▼$29.56$723.21M2.1698,623 shs474,785 shsSANASana Biotechnology$2.98-0.3%$3.70$1.26▼$7.30$711.04M1.886.25 million shs2.20 million shsTen Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBGMBGM Group+1.73%-6.95%-8.62%-41.71%-8.18%CCCCC4 Therapeutics+1.99%-0.78%+21.90%+74.15%-57.40%NRIXNurix Therapeutics+3.84%-0.94%-16.13%-24.32%-61.95%SANASana Biotechnology+5.28%-11.28%-29.31%+17.25%-46.61%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBGMBGM Group$7.41-2.9%$8.86$6.05▼$17.17$741.80M1.2625,631 shs6,886 shsCCCCC4 Therapeutics$2.67+4.3%$2.22$1.09▼$7.22$182.20M2.981.60 million shs1.31 million shsNRIXNurix Therapeutics$9.12-3.6%$10.99$8.18▼$29.56$723.21M2.1698,623 shs474,785 shsSANASana Biotechnology$2.98-0.3%$3.70$1.26▼$7.30$711.04M1.886.25 million shs2.20 million shsTen Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBGMBGM Group+1.73%-6.95%-8.62%-41.71%-8.18%CCCCC4 Therapeutics+1.99%-0.78%+21.90%+74.15%-57.40%NRIXNurix Therapeutics+3.84%-0.94%-16.13%-24.32%-61.95%SANASana Biotechnology+5.28%-11.28%-29.31%+17.25%-46.61%Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBGMBGM Group$25.10M28.70N/AN/A$7.34 per share1.01CCCCC4 Therapeutics$35.58M5.34N/AN/A$3.06 per share0.87NRIXNurix Therapeutics$54.55M12.78N/AN/A$7.44 per share1.23SANASana BiotechnologyN/AN/AN/AN/A$1.12 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBGMBGM Group-$1.44MN/A0.00∞N/AN/AN/AN/AN/ACCCCC4 Therapeutics-$105.32M-$1.58N/AN/AN/A-325.88%-53.91%-33.26%10/30/2025 (Estimated)NRIXNurix Therapeutics-$193.57M-$2.61N/AN/AN/A-234.57%-45.26%-34.71%10/10/2025 (Estimated)SANASana Biotechnology-$266.76M-$1.06N/AN/AN/AN/A-91.96%-43.07%11/14/2025 (Estimated)Latest CCCC, BGM, SANA, and NRIX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/11/2025Q2 2025SANASana Biotechnology-$0.20-$0.16+$0.04-$0.39N/AN/A8/7/2025Q2 2025CCCCC4 Therapeutics-$0.38-$0.37+$0.01-$0.37$5.24 million$6.46 million7/9/2025Q2 2025NRIXNurix Therapeutics-$0.79-$0.52+$0.27-$0.52$16.26 million$44.06 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBGMBGM GroupN/AN/AN/AN/AN/ACCCCC4 TherapeuticsN/AN/AN/AN/AN/ANRIXNurix TherapeuticsN/AN/AN/AN/AN/ASANASana BiotechnologyN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBGMBGM GroupN/A1.821.45CCCCC4 TherapeuticsN/A5.065.06NRIXNurix TherapeuticsN/A6.826.82SANASana BiotechnologyN/A2.472.47Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBGMBGM GroupN/ACCCCC4 Therapeutics78.81%NRIXNurix TherapeuticsN/ASANASana Biotechnology88.23%Insider OwnershipCompanyInsider OwnershipBGMBGM Group58.66%CCCCC4 Therapeutics8.73%NRIXNurix Therapeutics7.40%SANASana Biotechnology30.10%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBGMBGM Group29897.22 million40.19 millionN/ACCCCC4 Therapeutics15071.17 million64.96 millionOptionableNRIXNurix Therapeutics30076.45 million70.79 millionOptionableSANASana Biotechnology380237.81 million166.23 millionOptionableCCCC, BGM, SANA, and NRIX HeadlinesRecent News About These CompaniesSana Biotechnology, Inc. $SANA Shares Sold by Baker BROS. Advisors LPSeptember 4 at 6:27 AM | marketbeat.comSana Biotechnology, Inc. (SANA) Presents At Citi's Biopharma Back To School Conference TranscriptSeptember 2 at 11:01 PM | seekingalpha.comSana Biotechnology Announces Public Offering PricingAugust 28, 2025 | theglobeandmail.comSana Biotechnology to Present at September 2025 Investor ConferencesAugust 26, 2025 | globenewswire.comDeutsche Bank AG Has $1.12 Million Stock Holdings in Sana Biotechnology, Inc. $SANAAugust 26, 2025 | marketbeat.comCitizens JMP Reiterates a Buy Rating on Sana Biotechnology (SANA) With a $5 PTAugust 25, 2025 | msn.comBiotech’s Big Bang: IPOs, Uplists, and the Short Squeeze EffectAugust 21, 2025 | msn.comSana Biotechnology Announces Closing of Full Exercise of Underwriters’ Option to Purchase Additional SharesAugust 21, 2025 | uk.finance.yahoo.comSana Biotechnology Announces Closing of Full Exercise of Underwriters’ Option to Purchase ...August 21, 2025 | bakersfield.comBSana Biotechnology Announces Closing of Full Exercise of Underwriters' Option to Purchase Additional SharesAugust 20, 2025 | tmcnet.comSana Biotechnology, Inc. Completes Sale of 3,358,208 Shares, Generating Approximately $86.3 Million in Gross ProceedsAugust 20, 2025 | quiverquant.comQHC Wainwright Issues Optimistic Forecast for SANA EarningsAugust 16, 2025 | marketbeat.comSana Biotechnology drops Washington plant build-out, pivots to CDMOs insteadAugust 14, 2025 | fiercepharma.comFSana Biotechnology Reports Non-Cash Impairment LossesAugust 14, 2025 | theglobeandmail.comSana Biotech Bails on Factory in Old AT&T Call CenterAugust 12, 2025 | finance.yahoo.comSana Biotechnology (NASDAQ:SANA) Posts Earnings Results, Beats Estimates By $0.04 EPSAugust 12, 2025 | marketbeat.comSana Biotechnology, Inc. (NASDAQ:SANA) Given Average Rating of "Buy" by BrokeragesAugust 12, 2025 | marketbeat.comSana: Q2 Earnings SnapshotAugust 11, 2025 | sfgate.comSana suspends build-out of Bothell manufacturing facilityAugust 11, 2025 | bizjournals.comSana Biotechnology Reports Second Quarter 2025 Financial Results and Business UpdatesAugust 11, 2025 | manilatimes.netMSana Biotechnology: Fundraising Triggers Major Sell-Off, I'm Still IntriguedAugust 8, 2025 | seekingalpha.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCCCC, BGM, SANA, and NRIX Company DescriptionsBGM Group NASDAQ:BGM$7.41 -0.22 (-2.88%) Closing price 04:00 PM EasternExtended Trading$7.46 +0.05 (+0.67%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Qilian International Holding Group Limited manufactures and distributes active pharmaceutical ingredients (APIs), traditional Chinese medicine derivatives (TCMD), and other by-products in China. The company provides licorice products, including Gan Di Xin, an antitussive and expectorant medicine; Qilian Shan Licorice Extract, an ingredient for pharmaceutical companies to manufacture traditional licorice tablets; and Qilian Shan licorice liquid extract, a primary ingredient for medical preparation companies to produce compound licorice oral solutions. It offers Qilian Shan oxytetracycline tablets to prevent and treat a range of diseases in chickens, turkeys, cattle, swine, and human; and Qilian Shan oxytetracycline APIs for pharmaceutical companies to manufacture medications. In addition, the company offers TCMD products, such as Ahan antibacterial paste to treat refractory chronic skin diseases; heparin products, including heparin sodium preparations for pharmaceutical companies to produce medications for cardiovascular diseases, cerebrovascular diseases, and hemodialysis; and Zhu Xiaochang sausage casings, which are natural food products for culinary application. Further, it provides Xiongguan organic fertilizers to improve crop yield and soil's chemical properties and reduce soil compaction; and Xiongguan organic-inorganic compound fertilizers to increased plant growth. Qilian International Holding Group Limited was incorporated in 2019 and is based in Jiuquan, the People's Republic of China.C4 Therapeutics NASDAQ:CCCC$2.67 +0.11 (+4.30%) Closing price 04:00 PM EasternExtended Trading$2.66 -0.01 (-0.37%) As of 07:42 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting IKZF1 and IKZF3 for multiple myeloma and non-Hodgkin lymphomas, including peripheral T-cell lymphoma and mantle cell lymphoma, currently under Phase 1/2 clinical trials. The company is also developing CFT1946, an orally bioavailable BiDAC degrader targeting V600X mutant BRAF to treat melanoma, non-small cell lung cancer (NSCLC), colorectal cancer, and other solid malignancies, currently under Phase 1/2 clinical trials; and CFT8919, an orally bioavailable, allosteric, and mutant-selective BiDAC degrader of epidermal growth factor receptor, or EGFR, with an L858R mutation in NSCLC. It has strategic collaborations with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; Biogen MA, Inc.; Betta Pharmaceuticals, Co., Ltd.; and Merck Sharp & Dohme, LLC, as well as Calico Life Sciences LLC. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.Nurix Therapeutics NASDAQ:NRIX$9.12 -0.34 (-3.59%) Closing price 04:00 PM EasternExtended Trading$9.15 +0.04 (+0.38%) As of 05:52 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Nurix Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications. It is also developing NX-0479/GS-6791, a IRAK4 degrader for the treatment of rheumatoid arthritis and other inflammatory diseases. The company has a strategic collaboration agreement with Gilead Sciences, Inc., Sanofi S.A., and Seagen Inc. co-development and co-commercialization for multiple drug candidates. The company was formerly known as Nurix Inc. and changed its name to Nurix Therapeutics, Inc. in October 2018. Nurix Therapeutics, Inc. was incorporated in 2009 and is headquartered in San Francisco, California.Sana Biotechnology NASDAQ:SANA$2.98 -0.01 (-0.33%) Closing price 04:00 PM EasternExtended Trading$2.98 +0.00 (+0.17%) As of 07:31 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Sana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others. The company's product candidates include SC291 that is used as allogeneic cell therapies for hematologic malignancies; ARDENT for a potential treatment for non-Hodgkin's lymphoma, and chronic lymphoblastic leukemia; GLEAM, to treat multiple autoimmune disorders that involve production of autoimmune antibodies, including lupus nephritis, extrarenal lupus, antineutrophil cytoplasmic antibody -associated vasculitis, and others. It is developing SC262 to treat patients with relapsed and/or refractory B-cell malignancies; SC255 for multiple myeloma treatment; SC379, a therapy for patients with certain central nervous system disorders healthy allogeneic glial progenitor cells; SC451, a product candidate to treat diabetes, with an initial focus on type 1 diabetes mellitus; and UP421 that reduces long-term exogenous insulin dependence. The company has an option and license agreement with Beam Therapeutics Inc. for use of Beam's proprietary CRISPR Cas12b nuclease editing technology to research, develop, and commercialize engineered cell therapy products; and a license agreement with Harvard College to access certain intellectual property for the development of hypoimmune-modified cells. The company was formerly known as FD Therapeutics, Inc. and changed its name to Sana Biotechnology, Inc. in September 2018. Sana Biotechnology, Inc. was incorporated in 2018 and is headquartered in Seattle, Washington. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Palantir Insider Selling: Risk Signal or Normal Activity? Buy the Dip? GitLab’s Bullish Case Outweighs the Bears Affirm Crushes Earnings Expectations, Turns Bears into Believers Gold’s Explosive Rally: GDX ETF May Be the Fast Track to Profits Dollar Tree Plunges Into Buy-Zone: A Robust Rebound Is Expected Zscaler Shares Can Hit a Fresh High Before Year-End Why Qualcomm Is Outperforming NVIDIA After Months of Lagging Alphabet Stock Surges After Dodging Harsh Antitrust Remedies Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
